Point of Care Device for Ictus Diagnosis using Plasmatic Biomarkers: 2-Stroke-Chip. (Q3177441): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): In order to obtain a panel of biomarkers for its clinical application in the field of stroke and its incorporation into a rapid measuring device or POC, we intend to develop an ambitious project with neurologists, biologists and bioinformatics, which will allow a new phase of discovery of diagnostic biomarkers of stroke using aptámer technology, counting on molecular information of about 1,500 patients. A panel of markers that optimally discrimi...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Point of Care Device for Ictus Diagnosis using Plasmatic Biomarkers: 2-Stroke-Chip. | |||
Revision as of 18:50, 12 October 2021
Project Q3177441 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Point of Care Device for Ictus Diagnosis using Plasmatic Biomarkers: 2-Stroke-Chip. |
Project Q3177441 in Spain |
Statements
5,750.0 Euro
0 references
11,500.0 Euro
0 references
50.0 percent
0 references
1 January 2015
0 references
31 March 2017
0 references
FUNDACION PARC TAULI
0 references
41°32'31.56"N, 2°6'50.04"E
0 references
08187
0 references
Con el objetivo de obtener un panel de biomarcadores para su aplicación clínica en el ámbito del ictus y su incorporación en un dispositivo de medición rápida o POC, pretendemos desarrollar un ambicioso proyecto contando con neurólogos, biólogos y bioinformáticos, que permitirá llevar a cabo una nueva fase de descubrimiento de biomarcadores diagnósticos de ictus utilizando tecnología de aptámeros, contando así con información molecular de cerca de 1.500 pacientes. Del total de proteínas estudiadas y mediante el uso de herramientas computacionales y estadística comparativa, se seleccionará un panel de aquellos marcadores que discriminen de forma óptima a los pacientes con ictus y entre éstos, si son isquémicos o hemorrágicos. Con toda la información molecular recabada y mejorando el fenotipaje de los pacientes, se estudiará el papel de las proteínas estudiadas como biomarcadores pronósticos en pacientes con ictus. Una vez determinado el mejor panel de biomarcadores posible, procederemos a desarrollar un dispositivo POC de ensayo múltiple para llevarlo a la práctica clínica a corto plazo. Con el dispositivo piloto realizaremos un estudio de aplicabilidad clínica en hospitales comarcales de nuestra comunidad, donde este tipo de dispositivos podrían reducir el número de transferencias urgentes a hospitales de referencia ante la sospecha de ictus. Estas características hacen que este proyecto sea altamente transferible y tenga la capacidad de generar riqueza en el territorio a través de la comercialización de un producto de diagnóstico in vitro y de una enorme reducción del gasto sanitario en ictus, primera causa de muerte en mujeres españolas. (Spanish)
0 references
In order to obtain a panel of biomarkers for its clinical application in the field of stroke and its incorporation into a rapid measuring device or POC, we intend to develop an ambitious project with neurologists, biologists and bioinformatics, which will allow a new phase of discovery of diagnostic biomarkers of stroke using aptámer technology, counting on molecular information of about 1,500 patients. A panel of markers that optimally discriminates between patients with stroke and between these, if they are ischemic or hemorrhagic, will be selected from the total of proteins studied and through the use of computational tools and comparative statistics. With all the molecular information collected and improving the phenotyping of patients, the role of proteins studied as prognostic biomarkers in patients with stroke will be studied. Once the best possible biomarker panel is determined, we will proceed to develop a multi-assay POC device for short-term clinical practice. With the pilot device we will conduct a clinical applicability study in regional hospitals in our community, where this type of device could reduce the number of urgent transfers to reference hospitals in the event of suspicion of stroke. These characteristics make this project highly transferable and have the capacity to generate wealth in the territory through the commercialisation of an in vitro diagnostic product and a huge reduction in health expenditure on stroke, the leading cause of death in Spanish women. (English)
12 October 2021
0 references
Sabadell
0 references
Identifiers
DTS14_00108
0 references